|
|
Article: Anadys Pharmaceuticals and LG Life Sciences Report Activity Against Lamivudine-Resistant Strains in Phase II Clinical Trial of ANA380 for Hepatitis B; New Data From Ongoing Trial of ANA380 Presented at EASL Annual Meeting in Paris.
- Article from:
- PR Newswire
- Article date:
- April 18, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, April 18 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd. reported positive new data from an ongoing Phase II clinical trial of ANA380 (LB80380) in patients with lamivudine-resistant hepatitis B virus (HBV) infection at the 40th Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris.
Ching-Lung Lai, M.D., Professor in the Department of Medicine at the University of Hong Kong and co-investigator of the study, reported that oral administration of ANA380 over 12 weeks reduced DNA viral load by an average of 3.9 log10 units, or more than 99.9 percent, in lamivudine-resistant patients ...